8 - 8:30 |
Registration |
8:30 - 8:40 |
Welcome from DOE
Susan Rose |
8:40 - 8:50 |
Welcome on Behalf of the Planning Committee
Sally Tinkle |
8:50- 9:35 |
Multi-Disciplinary Research-the Key to Solving the Beryllium
Disease Puzzle
Kathleen Kreiss |
Session 1. Immunopathology of Beryllium-Induced Granulomatous
Disease
Session chair: Brian Kotzin
|
9:35 - 10:15 |
Immunopathogenesis of Sarcoidosis
Gianpietro Semanzato |
10:15 - 10:30 |
Break |
10:35 -10:55 |
Characterization of Beryllium-Specific Memory CD4+ T Cells
in Patients with Chronic Beryllium Disease
Andrew P. Fontenot, Scott J. Canavera, Laia Gharavi, Lee S. Newman,
and Brian L. Kotzin |
10:55 - 11:15 |
HLA-DP-Unrestricted TNF-a Release in Be-Stimulated PBMC from
Berylliosis Patients
Massimo Amicosante, Floriana Berretta, Alberto Franchi, Paola Rogliani,
Chiara Dotti, Monica Losi, Raed Dweik, and Cesare Saltini |
11:15 - 11:35 |
Design, Engineering and Production of Human Recombinant T Cell
Receptor Ligands Derived from HLA-DP
Gregory G. Burrows, Roberto Meza-Romero, Jeff Mooney, Justin W.
Chang, Hans Peter Bachinger, and Jianya Huan |
11:35 - 11:55 |
A Flow Cytometric Assay for Beryllium Sensitization: Screening
and Mechanistic Applications
A.J. Jabbour, R.A. Ponce, M.T. Rosato, T.J. Kavanagh, L.S. Newman,
T.K. Takaro, and E.M. Faustman |
12:00 - 1:00 |
Lunch |
Session 2. Pulmonary Signaling Pathways Activated by Beryllium
Session chair: Lisa Maier |
1:00 - 1:45 |
Second Messenger Pathways Activated by Endotoxin and Asbestosis
in Alveolar Macrophages
Gary Hunninghake |
1:45- 2:05 |
Beryllium Stimulates a Local Angiotensin System in Chronic
Beryllium Disease
T. Hendry-Hofer, A.F. Fontenot, E.A. Barker, M. Boguniewicz, L.S.
Newman, and L.A. Maier |
2:05 - 2:25 |
High Levels of Nitric Oxide (NO) in Exhaled Breath in Patients
with Chronic Beryllium Disease
R.A. Dweik, D. Laskowski, and S.C. Erzurum |
2:25 - 2:45 |
Nitric Oxide (NO) Attenuation of Interferon Gamma (IFN-Gamma)
Responses in Chronic Beryllium Disease (CBD): Evidence for Mechanisms
Independent of Interleukin (IL)-18
M.J. Thomassen, C. Farver, R.A. Dweik, D. Culver, B. Yen-Lieberman,
M. Kavuru, and B.P. Barna |
2:45 - 3:00 |
Break |
Session 3. Physico-Chemical Properties of Beryllium Metal and
Alloys
Session chair: Babetta Marrone |
3:00 - 3:45 |
Physicochemical Determinants of Beryllium Toxicity Using In
Vitro and In Vivo Models
Greg Finch |
3:45 - 4:05 |
Dosimetry of Beryllium in an Animal Model by Accelerator Mass
Spectrometry
M.L. Chiarappa-Zucca, R.C. Finkel, J.E. McAninch, R.E. Martinelli,
and K.W.Turteltaub |
4:05 - 4:25 |
Identification of Non-Toxic Beryllium-Chelating Porphyrins
and Method of Delivery to Mice in an Attempt to Reduce the Lung
Beryllium (Be) Burden in Chronic Beryllium Disease (CBD)
Jim Klostergaard and George P. Sakalosky |
4:25 - 4:45 |
Surface Area of Respirable Beryllium Metal, Oxide, and Copper
Alloy Aerosols and Implications for Assessment of Exposure Risk
of Chronic Beryllium Disease
A.B. Stefaniak, M.D. Hoover, R.M. Dickerson, E.J. Peterson, G.A.
Day, P.N. Breysse, M.S. Kent, and R.C. Scripsick |
4:45 - 5:05 |
Examining Beryllium Chemistry with Modern Analytical Techniques
M. Sutton, S.R. Burastero, C. Mundy, and J. Quong |
5:05 |
Social gathering-location to be announced |
Wednesday, June 26, 2002
|
Session 4. Gene - Exposure Interactions
Session chair: Cesare Saltini
|
9 - 9:45 |
Chemicals + Immunologic Lung Disease: Gene + Environment
Anthony Newman-Taylor |
9:45 - 10:05 |
Functional TNF-a Promoter Polymorphisms
Associated with Chronic Beryllium Disease and Beryllium-Induced
TNF-a
L.A. Maier, R.T. Sawyer, T. Hendry-Hofer, C. Parsons, R. Bauer,
D. McGrath, P. Lympany, R. duBois, and L.S. Newman |
10:05 - 10:25 |
Association of HLA Class II Markers and Beryllium Hypersensitivity
and Disease: Reevaluation of Previously Published Data After 4-8
Years of Follow-up
C. Saltini and M. Rossman |
10:25 - 10:45 |
Electrostatic Potential on HLA-DP*1701 and HLA-DP*0401: Implications
for Putative Mechanism of Chronic Beryllium Disease
James A. Snyder, Ainsley Weston, Sally T. Tinkle, and Eugene Demchuk |
10:45 - 11:00 |
Break |
Session 5. New Directions in Pulmonary Research
Session chair: Milton Rossman
|
11:00 - 11:45 |
Effects and Fate of Ultrafine Particles
Günter Oberdörster |
11:45 - 1:00 |
Lunch |
1:00 - 1:20 |
Cutaneous Application of Beryllium Salts and Oxide Particles
Produces Peripheral Sensitization in the C3H/HeOuJ Mice
Sally S. Tinkle, James M. Antonini, Jenny R. Roberts, Rebecca Salmen,
Karyn Depree, and Melanie Flint |
1:20 - 1:40
|
In Vitro Transformation of Phagocytized Beryllium Oxide Particles
in the Murine J774A.1 Cell
G.A. Day, A.B. Stefaniak, M.D. Hoover, R.M. Dickerson, E.J. Peterson,
N.A. Esmen, and R.C. Scripsick |
1:40 - 2:00 |
The Mouse Deep Lung is Exposed to Respirable Particles Administered
by Pharyngeal Aspiration
A.F. Hubbs, G.V.S. Rao, M. Kashon, R. Salmen, L.A. Battelli, P.
Willard, J. Antonini, D.N. Weissman, and S. Tinkle |
2:00 - 2:20 |
Beryllium-Induced Macrophage Apoptosis in Chronic Beryllium
Disease
R.T. Sawyer, V.A. Fadok, L.A. Maier, L.A. Kittle, J.M. Routes, and
L.S. Newman |
2:20 - 2:35 |
Break |
2:35 - 3:35 |
Ethical, Legal and Social Implications of Beryllium Exposure
and Research: Case Presentation
Panel: Reed Durham, beryllium chemist; Myron Harrison, occupational
medicine; Jon Moreno, bioethicist; Susan Rose, bioethicist |
3:35 - 3:55 |
Meeting Overview - Lee Newman |
3:55 - 4:00 |
Closing Remarks - Sally Tinkle |